These data suggest that simultaneous inhibition of stemness marker genes—such as OCT4, KLF4, SOX2, c-MYC, and NANOG, as well as TERT, JDP2, HIF1α, and BMI1—could become an effective means of cancer treatment by depriving residual CSCs of their self-renewal capacity. The gene discussed is MYC; the disease is cancer.